FY2027 EPS Estimates for Insmed Decreased by Leerink Partnrs

Insmed, Inc. (NASDAQ:INSM) – Leerink Partnrs dropped their FY2027 earnings estimates for Insmed in a report released on Tuesday, September 2nd. Leerink Partnrs analyst J. Schwartz now expects that the biopharmaceutical company will earn ($2.52) per share for the year, down from their previous estimate of ($2.51). The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s revenue was up 18.9% on a year-over-year basis. During the same period last year, the company posted ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS.

INSM has been the subject of several other reports. Citigroup raised shares of Insmed to a “buy” rating in a research note on Tuesday, June 10th. Wells Fargo & Company increased their price target on shares of Insmed from $140.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday. Truist Financial increased their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. HC Wainwright increased their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Finally, Mizuho increased their price target on shares of Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 13th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.79.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $145.10 on Friday. The company has a market cap of $30.67 billion, a price-to-earnings ratio of -25.41 and a beta of 0.97. The company has a 50-day moving average price of $114.64 and a 200-day moving average price of $89.66. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed has a 12 month low of $60.40 and a 12 month high of $146.84.

Insider Activity at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the firm’s stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares of the company’s stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO William Lewis sold 6,865 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $128.40, for a total transaction of $881,466.00. Following the sale, the chief executive officer directly owned 233,924 shares of the company’s stock, valued at $30,035,841.60. This trade represents a 2.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 535,320 shares of company stock valued at $54,581,793 over the last ninety days. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

Institutional investors and hedge funds have recently made changes to their positions in the company. M&T Bank Corp boosted its holdings in Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC boosted its holdings in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 158 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Insmed by 24.8% in the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 186 shares during the last quarter. ORG Partners LLC boosted its holdings in Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the last quarter. Finally, Cullen Frost Bankers Inc. boosted its holdings in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 221 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.